Journal of Medicinal Chemistry · 2013 · 53 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignSteroid BiochemistryStructure-activity RelationshipsEndocrine PharmacologyHormonal TherapySteroid Hormone BiochemistrySteroid MetabolismSteroid PharmacologyAromatase ActivityAromatase InhibitionAromatase InhibitorsDocking-based Drug DesignEstrogen MetabolitesEstrogen PharmacologyEstrogen ReceptorsPharmacokinetic Parameters
The first synthesis of the tamoxifen metabolite norendoxifen is reported. This included syntheses of (E)-norendoxifen, (Z)-norendoxifen, and (E,Z)-norendoxifen isomers. (Z)-Norendoxifen displayed affinity for aromatase (Ki 442 nM), estrogen receptor-α (EC50 17 nM), and estrogen receptor-β (EC50 27.5 nM), while the corresponding values for (E)-norendoxifen were aromatase (Ki 48 nM), estrogen receptor-α (EC50 58.7 nM), and estrogen receptor-β (EC50 78.5 nM). Docking and energy minimization studies were performed with (E)-norendoxifen on aromatase, and the results provide a foundation for structure-based drug design. The oral pharmacokinetic parameters for (E,Z)-norendoxifen were determined in mice, and (Z)-norendoxifen was found to result in significantly higher plasma concentrations and exposures (AUC values) than (E)-norendoxifen. The affinities of both isomers for aromatase and the estrogen receptors, as well as the pharmacokinetic results, support the further development of norendoxifen and its analogues for breast cancer treatment.
16
Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text
Medicine, Endocrinology, Oncology +14
M Baum, Aman U. Budzar, J Cuzick et al. · The Lancet · 2002 · 2K citations
Pharmacy, Oncology, Pharmacotherapy +13